Keywords
Squamous Cell
Staging
Treatment
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To discuss and review the general aspects inherent to Cutaneous Squamous Cell Carcinoma (SCC). Bibliographic review: SCC is the second most common non-melanoma skin cancer and the main risk factors are exposure to ultraviolet radiation, fair skin, immunosuppression and age. Suspicion begins with the interpretation of clinical information, such as the patient's history, anatomical location, morphology, and appearance. The subtypes are in situ SCC, keratoacanthoma and invasive SCC. There is still no universally accepted staging system for CEC. The first-line treatment is surgical excision, with Mohs micrographic surgery being the most efficient and with high cure rates. However, in advanced cases, it is common to use other adjuvant therapies. Final considerations: Due to its increasing incidence, SCC has been gaining great attention in clinical practice. However, there are still difficulties in establishing a universal staging, as well as understanding its prognosis. Therefore, further studies are needed to establish a universally accepted staging and curative treatment for all types of SCC.
References
ALAM M, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol., 2018;78(3): 560-578.
BRANCACCIO G, et al. Risk Factors and Diagnosis of Advanced Cutaneous Squamous Cell Carcinoma. Dermatol Pract Concept, 2021; 11(Suppl 2): e2021166S.
CLAVEAU J, et al. Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma. Curr Oncol., 2020; 27(4): e399-e407.
COMBALIA A e CARRERA C. Squamous Cell Carcinoma: An Update on Diagnosis and Treatment. Dermatol Pract Concept, 2020; 10(3): e2020066.
CORCHADO-COBOS R, et al. Cutaneous Squamous Cell Carcinoma: From Biology to Therapy. Int J Mol Sci., 2020; 21(8): 2956.
FANIA L, et al. Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines, 2021; 9(2): 171.
FOX M, et al. Nodal staging of high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2019; 81(2): 548-557.
GOLDIE SJ, et al. Targeted Therapy Against the Cell of Origin in Cutaneous Squamous Cell Carcinoma. Int J Mol Sci., 2019; 20(9): 2201.
HEDBERG ML, et al. Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma. Int J Mol Sci., 2022; 23(7): 3478.
JONG E, et al. Update of advanced cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol., 2022; 36(1): 6-10.
KEEPING S, et al. Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma. Future Oncology, 2020; 17(05).
MIGDEN MR, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol., 2020; 21(2): 294-305.
MORENO-RAMÍREZ D, et al. Surgery for Cutaneous Squamous Cell Carcinoma and its Limits in Advanced Disease. Dermatol Pract Concept, 2021; 11(Suppl 2): e2021167S.
NEWMAN JG, et al. Adjuvant therapy for high-risk cutaneous squamous cell carcinoma: 10-year review. Head Neck, 2021; 43(9): 2822-2843.
QUE SKT, et al. Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol., 2018; 78(2): 237-247.
RIIHILA P, et al. Complement System in Cutaneous Squamous Cell Carcinoma. Int J Mol Sci., 2019; 20(14): 3550.
ROGERS HW, et al. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol., 2015; 151(10): 1081–1086.
SÁNCHEZ-DANÉS A e BLANPAIN C. Deciphering the cells of origin of squamous cell carcinomas. Nat Rev Cancer, 2018; 18(9): 549-561.